Skip to content

SABS

SAB Biotherapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.51
+0.29%
Ask drillr

Next report

Analyst consensus

Next report date
Nov 13, 2026
EPS estimate
-$0.27
Revenue estimate
$125.0K

Latest reported

Last report date
Aug 6, 2026
EPS actual
-$0.28
EPS estimate
-$0.28
Revenue actual
Revenue estimate
$125.0K

Track record

Trailing twelve quarters

EPS beats (12Q)
6
EPS misses (12Q)
5
EPS in line (12Q)
1
Avg surprise (4Q)
-29.6%
Revenue beats (12Q)
0
Reported history
Report dateEPS estimateEPS actualSurpriseRevenue actual
Aug 6, 2026-$0.28-$0.28Beat 1.06%
May 12, 2026-$0.20-$0.35Miss -75.00%
Mar 11, 2026-$0.22-$0.46Miss -109.03%
Nov 14, 2025-$0.59-$0.21Beat 64.41%
Aug 7, 2025-$0.82-$1.09Miss -32.93%
May 9, 2025-$1.00-$0.56Beat 44.00%
Mar 28, 2025-$1.16-$1.23Miss -6.03%$100.0K
Aug 8, 2024-$1.13-$0.79Beat 30.09%$263.1K
May 20, 2024-$0.98-$0.54Beat 44.90%$944.6K
Nov 13, 2023-$1.00-$1.00In line
Aug 21, 2023-$1.60-$1.40Beat 12.50%$85.5K
May 16, 2023-$0.80-$1.50Miss -87.50%$600.0K

Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 17, 2026